2002Zhejiang Cancer JournalRequires access

Continuous Infusion 5-Fluorouracil and Low Dose Cisplatin for the Treatment of Advanced Gastric Cancer in 53 Cases

Tian Wei-wei

Open publisher page 0 citations

Abstract

To observe the response and toxicity of combination chemotherapy with continuous infusion 5-fluorouracil(5-Fu) and low dose cisplatin (DDP) in patients with advanced gastric cancer.Fifty-three patients with advanced gastric cancer (treatment group)were treated by combination chemotherapy of continuous infusion 5-Fu 350mg/m2·d for 8~24 hours for twenty-eight days,and DDP 5mg/m2·d,infused for five times in one week for four weeks.Patients received 2 cycles of treatment. The control group(fifty-three patients with advanced gastric cancer)was treated by FAM/FMP (5-Fu+MMC+ADM/DDP)regimen.The response rate in treatment group was 60.37%,39.62% in control group.There was a difference(P0.05) among them.The toxicity of chemotherapy such as nausea,vomiting,mylodepression in control group was higher than that in treatment group. [Conclusion] A higher response rate with mild toxicity is attainable in patients with advanced gastric cancer treated by combination of 5-Fu in continuous infusion and low dose DDP .

About this research paper

What this paper is about

To observe the response and toxicity of combination chemotherapy with continuous infusion 5-fluorouracil(5-Fu) and low dose cisplatin (DDP) in patients with advanced gastric cancer.Fifty-three patients with advanced gastric cancer (treatment group)were treated by combination chemotherapy of continuous infusion 5-Fu 350mg/m2·d for 8~24 hours for twenty-eight days,and DDP 5mg/m2·d,infused for five times in one week for four weeks.Patients received 2 cycles of treatment. The control group(fifty-three patients with advanced gastric cancer)was treated by FAM/FMP (5-Fu+MMC+ADM/DDP)regimen.The response rate in treatment group was 60.37%,39.62% in control group.There was a difference(P0.05) among them.The toxicity of chemotherapy such as nausea,vomiting,mylodepression in control group was higher than that in treatment group. [Conclusion] A higher response rate with mild toxicity is attainable in patients with advanced gastric cancer treated by combination of 5-Fu in continuous infusion and low dose DDP .

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

To observe the response and toxicity of combination chemotherapy with continuous infusion 5-fluorouracil(5-Fu) and low dose cisplatin (DDP) in patients with advanced gastric cancer.Fifty-three patients with advanced gastric cancer (treatment group)were treated by combination chemotherapy of continuous infusion 5-Fu 350mg/m2·d for 8~24 hours for twenty-eight days,and DDP 5mg/m2·d,infused for five times in one week for four weeks.Patients received 2 cycles of treatment. The control group(fifty-three patients with advanced gastric cancer)was treated by FAM/FMP (5-Fu+MMC+ADM/DDP)regimen.The response rate in treatment group was 60.37%,39.62% in control group.There was a difference(P0.05) among them.The toxicity of chemotherapy such as nausea,vomiting,mylodepression in control group was higher than that in treatment group. [Conclusion] A higher response rate with mild toxicity is attainable in patients with advanced gastric cancer treated by combination of 5-Fu in continuous infusion and low dose DDP .

Key concepts: Fluorouracil, Medicine, Nausea, Cisplatin, Vomiting, Regimen, Chemotherapy, Toxicity

Related papers

Back to paper searchBrowse research topicsOriginal source
Continuous Infusion 5-Fluorouracil and Low Dose Cisplatin for the Treatment of Advanced Gastric Cancer in 53 Cases — Research Paper | ScholarLens